Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension

Pulmonary Circulation

Volumn 5, Issue 4, 2015, Pages 640-648

  Ross, David J ^a   Hough, Greg ^a   Hama, Susan ^a   Aboulhosn, Jamil ^a   Belperio, John A ^a   Saggar, Rajan ^a   Van Lenten, Brian J ^a   Ardehali, Abbas ^a   Eghbali, Mansoureh ^a   Reddy, Srinivasa ^a   Fogelman, Alan M ^a   Navab, Mohamad ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

High density lipoprotein; Hydroxyeicosatetraenoic acids; Hydroxyoctadecadienoic acids; Inflammatory index; Low density lipoprotein; Pulmonary arterial endothelial cells; Pulmonary arterial hypertension; Pulmonary arterial smooth muscle cells

Indexed keywords

EID: 85026339123     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/683695     Document Type: Article

References (46)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 suppl.): D34-D41.
2. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121(18):2045-2066.
3. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144(2):275-285.
4. Voelkel NF, Tuder R. Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann NY Acad Sci 1994;725:104-109.
5. Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165(10): 1419-1425.
6. Dorfmüller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165(4):534-539.
7. Ross DJ, Strieter RM, Fishbein MC, Ardehali A, Belperio JA. Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension. J Heart Lung Transplant 2012;31(8): 865-873.
8. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamaiah GM, Fogelman AM, Reddy ST. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more antiinflammatory HDL in mice. Drug Metab Lett 2010;4(3):139-148.
9. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007;100(11 suppl. 1):S32-S40.
10. Deigner HP, Hermetter A. Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol 2008;19(3):289-294.
11. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006;69(1):36-45.
12. Lähteenmäki TA, Seppo L, Laakso J, Korpela R, Vanhanen H, Tikkanen MJ, Vapaatalo H. Oxidized LDL from subjects with different dietary habits modifies atherogenic processes in endothelial and smooth muscle cells. Life Sci 2000;66(5):455-465.
13. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103(18):2283-2288.
14. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, et al. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 2011;75(7):1533-1538.
15. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009;284(27):18292-18301.
16. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8(4):222-232.
17. Navab M, Anantharamaiah GM, Fogelman AM. The role of highdensity lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15(4): 158-161.
18. Navab M, Reddy ST, Van Lenten BJ, Buga GM, Hough G, Wagner AC, Fogelman AM. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscl Thromb Vasc Biol 2012;32(11):2553-2560.
19. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008 49(6):1344-1352.
20. Van Lenten BJ, Wagner AC, Jung CL, Waring AJ, Ruchala P, Lehrer RI, Watson AD, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J LipidRes 2008;49(11):2302-2311.
21. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009;76(4): 437-444.
22. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014; 130(9):776-785.
23. Mahfouz MM, Kummerow FA. High density lipoprotein can modulate the inhibitory effect of oxLDL on prostacyclin generation by rat aorta in vitro. Prostaglandins Other Lipid Mediat 2003;72(3 4):91-114.
24. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-1932.
25. Archer SL, Chesler E, Cohn JN, Weir EK. ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog. J Am Coll Cardiol 1986;8(5):1189-1194.
26. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New Engl J Med 1996;334(5):296-301.
27. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Int Med 1994;121(6):409-415.
28. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, Keogh A, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-804.
29. Mahfouz MM, Kummerow FA. Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats. Prostaglandins Other Lipid Mediat 2005;76(1 4):59-73.
30. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatinsimvastatin study. Am J Physiol Lung Cell Mol Physiol 2007;293(4): L933-L940.
31. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010;181(10):1106-1113.
32. Watson G, Oliver E, Zhao L, Wilkins MR. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). In: Humbert M, Evgenov OV, Stasch JP, eds. Pharmacotherapy of pulmonary hypertension. Handb Exp Pharmacol 2013;218:531-548. doi: 10.1007/978-3-642-38664-0_21.
33. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, Loscalzo J, Kimmel SE, Christman BW, Barst RJ. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006;27(3):578-584.
34. Zeng WJ, Xiong CM, Zhao L, Shan GL, Liu ZH, Xue F, Gu Q, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J 2012;40(1):67-74.
35. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001;164(6): 1038-1042.
36. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001;88(6):555-562.
37. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171(5):494-499.
38. McLoughlin P, Hyvelin JM, Howell K. Pulmonary hypertension. New Engl J Med 2005;352(4):418-419.
39. Ma C, Li Y, Ma J, Liu Y, Li Q, Niu S, Shen Z, Zhang L, Pan Z, Zhu D. Key role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension. Hypertension 2011;58(4):679-688.
40. Ma J, Zhang L, Li S, Liu S, Ma C, Li W, Falck JR, et al. 8,9-Epoxyeicosatrienoic acid analog protects pulmonary artery smooth muscle cells from apoptosis via ROCK pathway. Exp Cell Res 2010; 316(14): 2340-2353.
41. Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Glück T, Fröhlich D, Krämer BK, Rothe G, Schmitz G. Changes in HDLassociated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009; 35(11): 1877-1885.
42. Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Renal Nutr 2013;23(3):203-206.
43. Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Apolipoprotein A-I mimetics. Curr Opin Lipidol 2014;25(4):304-308.
44. Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta Mol Cell Biol Lipids 2014;1841(1):162-167.
45. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. Highdensity lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014;114(1):171-182.
46. Fogelman AM. Trying to harness the potential of HDL: wishful thinking or sound strategy? Eur Heart J 2014;35(46):3248-32479.